Abstract

BackgroundPatients with early breast cancer (EBC) achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) have a favorable prognosis. Breast surgery might be avoided in patients in whom the presence of residual tumor can be ruled out with high confidence. Here, we investigated the diagnostic accuracy of contrast-enhanced MRI (CE-MRI) in predicting pCR and long-term outcome after NACT.MethodsPatients with EBC, including patients with locally advanced disease, who had undergone CE-MRI after NACT, were retrospectively analyzed (n = 246). Three radiologists, blinded to clinicopathologic data, reevaluated all MRI scans regarding to the absence (radiologic complete remission; rCR) or presence (no-rCR) of residual contrast enhancement. Clinical and pathologic responses were compared categorically using Cohen’s kappa statistic. The Kaplan-Meier method was used to estimate recurrence-free survival (RFS) and overall survival (OS).ResultsOverall rCR and pCR (no invasive tumor in the breast and axilla (ypT0/is N0)) rates were 45% (111/246) and 29% (71/246), respectively. Only 48% (53/111; 95% CI 38–57%) of rCR corresponded to a pCR (= positive predictive value - PPV). Conversely, in 87% (117/135; 95% CI 79–92%) of patients, residual tumor observed on MRI was pathologically confirmed (= negative predictive value - NPV). Sensitivity to detect a pCR was 75% (53/71; 95% CI 63–84%), while specificity to detect residual tumor and accuracy were 67% (117/175; 95% CI 59–74%) and 69% (170/246; 95% CI 63–75%), respectively. The PPV was significantly lower in hormone-receptor (HR)-positive compared to HR-negative tumors (17/52 = 33% vs. 36/59 = 61%; P = 0.004). The concordance between rCR and pCR was low (Cohen’s kappa − 0.1), however in multivariate analysis both assessments were significantly associated with RFS (rCR P = 0.037; pCR P = 0.033) and OS (rCR P = 0.033; pCR P = 0.043).ConclusionPreoperative CE-MRI did not accurately predict pCR after NACT for EBC, especially not in HR-positive tumors. However, rCR was strongly associated with favorable RFS and OS.

Highlights

  • Neoadjuvant chemotherapy (NACT) has become standard care for most patients with high-risk early breast cancer (EBC)

  • In 87% (117/135; 95% 95% Confidence interval (CI) 79–92%) of patients, residual tumor observed on Magnetic resonance imaging (MRI) was pathologically confirmed (= negative predictive value - NPV)

  • RCR was strongly associated with recurrence-free and overall survival and added prognostic information to the pathologic risk classification

Read more

Summary

Introduction

Neoadjuvant chemotherapy (NACT) has become standard care for most patients with high-risk early breast cancer (EBC). This is especially true for triple-negative and human epidermal growth factor receptor (HER2)-positive disease, where high rates of pathologic complete response (pCR) can be achieved [1,2,3]. Patients undergoing NACT have been shown to have a moderately higher risk of local recurrence after 15 years compared to patients treated with adjuvant chemotherapy (21.4% vs 15.9%; rate ratio 1.37; 95% CI 1.17–1.61; P = 0.0001) [4] This might - at least in part - be attributed to the higher rate of breast conservation after NACT [4], where potentially residual disease is not resected. Patients with early breast cancer (EBC) achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) have a favorable prognosis. We investigated the diagnostic accuracy of contrastenhanced MRI (CE-MRI) in predicting pCR and long-term outcome after NACT

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call